Gilead Stock Dives As Light Profit Overshadows Strong Cancer Drug Sales

Biotech giants Gilead Sciences (GILD) and Amgen (AMGN) posted mixed quarters — leading GILD stock and Amgen stock to topple Friday. X For Gilead, total revenue inched down roughly 4% to $6.35 billion, a hair above forecasts for $6.33 billion, according to FactSet. Adjusted earnings came in at…#gileadsciences #gild #amgen #amgn #gilead #covidsalesdive #veklury #merck #roche #rhhby
Source: Reuters: Health - Category: Consumer Health News Source Type: news